Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome

Status Terminated

Clinical Trial Summary

The Hepatopulmonary syndrome (HPS) results from intrapulmonary microvascular dilatation that impairs arterial oxygenation in the setting of cirrhosis or portal hypertension. As many as 10-20% of cirrhotics being evaluated for orthotopic liver transplantation (OLT) have advanced HPS and mortality is greater in those with HPS than in those without HPS. Currently, OLT is the only effective treatment, although post-operative mortality in HPS is increased relative to cirrhotic patients without HPS, with a one-year survival of between 68-80 %. Therefore, an effective medical therapy for advanced HPS could improve both pre-operative and post-operative mortality.

Recent work in experimental models of HPS has revealed that both nitric oxide synthase-derived nitric oxide and heme oxygenase-derived carbon monoxide cause intrapulmonary vasodilatation. These alterations appear to be driven in part by TNF-α modulation of pulmonary blood flow and intravascular monocyte accumulation. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with inhibitory effects on TNF-α and has recently been shown to be beneficial in patients with severe alcoholic hepatitis where TNF-α overproduction contributes to liver injury. In experimental HPS, pentoxifylline administration also decreases the severity of oxygenation abnormalities. However, pentoxifylline therapy has been associated with dose limiting side effects in patients with liver disease and the tolerability of pentoxifylline in cirrhotic patients with advanced HPS is unknown. Therefore, this open label single arm clinical trial was designed to evaluate the efficacy and tolerability of 8 weeks of pentoxifylline in cirrhotic patients with advanced HPS being considered for OLT.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00593658
Study type	Interventional
Source	University of Alabama at Birmingham
Contact
Status	Terminated
Phase	Phase 1
Start date	June 2004
Completion date	October 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01676597` - Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome	N/A
Terminated	`NCT01518595` - Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis	Phase 2
Completed	`NCT00362752` - A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome	Phase 2
Active, not recruiting	`NCT03092401` - Hepatopulmonary Syndrome and Postoperative Complications After Liver Transplantation : A Case-control Study	N/A
Not yet recruiting	`NCT05373134` - Efficacy and Safety of Pentoxifylline in Improving Oxygenation in Hepatopulmonary Syndrome	N/A
Terminated	`NCT02021929` - Sorafenib for Hepatopulmonary Syndrome	Phase 2
Completed	`NCT02148536` - Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome
Recruiting	`NCT03435406` - Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China	N/A
Recruiting	`NCT04004104` - Supine Exercise in Hepatopulmonary Syndrome Patients With Orthodeoxia	N/A
Terminated	`NCT04577001` - Letrozole in Patients With Hepatopulmonary Syndrome	Phase 2